This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Athenahealth Delivers 96 Percent Meaningful Use Attestation Rate Among Participating Providers

Stocks in this article: ATHN

athenahealth, Inc. (NASDAQ: ATHN), a leading provider of cloud-based electronic health record ( EHR), practice management, and care coordination services to medical groups and health systems, today announced that 96 percent of the company’s participating providers successfully attested for 2012 Medicare Meaningful Use Stage 1, Year 1. The company’s 96 percent attestation builds on the 85 percent rate delivered against 2011 Medicare Meaningful Use Stage 1, Year 1 and more than doubles the industry average (low 40 percent).

Jonathan Bush, CEO and Chairman of athenahealth, said, “Our Medicare Meaningful Use attestation rate is the proof in the pudding for cloud-based HIT services. This isn’t just a statistic: successful attestation represents real improvement in our client caregivers’ patient workflows, not to mention receipt of government MU incentive funds. It makes a tangible difference for our clients, which is what we work to do every day.”

The New England Journal of Medicine (NEJM) recently reported 12 percent of eligible Medicare providers nationwide have successfully attested to Meaningful Use.

Bush continued, “Ironically, this latest evidence of the superiority of the cloud model comes just on the heels of CMS [Centers for Medicare & Medicaid Services] issuing yet another in a series of Meaningful Use program delays. While our software-based competition insists that the MU program sets the bar too high and moves too fast, our results prove otherwise. While we sympathize with CMS having to reconcile athenahealth’s average 90 percent success rate across MU Stage 1 with the persistent failures of our competitors, we are disappointed that CMS continues to prop up health information technology’s laggards. If health information technology is ever to catch up with the rest of the information economy, we cannot afford to keep hitting the brakes.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs